AMLA II
Natural health product licensed in Canada
- Other names
- AMLA 2.0
- Licence holder
- Advanced Orthomolecular Research Inc.
- NPN or DIN-HM
- 80088426
- Status
- Active licence
- Licence date
- 21 September 2018
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Dose déclarée au-delà d'une limite
Zinc: up to 40 mg a day according to the dosing instructions published by Health Canada (4 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 15 mg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- À vérifier
Zinc: up to 40 mg a day according to the dosing instructions published by Health Canada, above the limite de sécurité from EFSAEuropean Food Safety Authority. for adults (25 mg a day). Le repère de l'EFSA porte sur l'apport total d'une journée, alimentation et compléments.
limite supérieure de sécurité (UL). EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), retrieved 21 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Zinc Source : Citrate de zinc | 10 mg | 40,000 µg |
| Phyllanthus emblica Source : Fruit Extract : Matériel brut sec Extraction ratio : 20:1 Dry plant equivalent : 5 g Potency : 4 % Gallic acid | 250 mg | Not calculated |
| Phyllanthus emblica Source : Fruit Potency : 60 % Tannins | Not specified | Not calculated |
Non-medicinal ingredients
Hypromellose, Stéaryl fumarate de sodium, Cellulose microcristalline
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 2 Capsule | 2 Tous les jours |
Uses authorised in Canada
Helps to maintain the body¿s ability to metabolize nutrients. Source of antioxidants that help reduce the oxidative damage caused by free radicals. Amla promotes the production of glutathione, an important antioxidant in the body, to fight/protect (cell) against/reduce (the oxidative effect of/the oxidative damage caused by/cell damage caused by) free radicals. Amla helps protect against oxidative stress by serving as a natural source of antioxidants. Amla helps to reduce C-reactive protein levels, a clinical marker of inflammation. Amla helps decrease low density lipoprotein, cholesterol and inhibit collagen induced platelet aggregation which contribute to the maintenance of normal cardiovascular function/health. Helps in connective tissue formation; helps to maintain healthy skin and helps to maintain immune function.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
If you are pregnant or breastfeeding, consult a health care practitioner prior to use. If you have or develop abdominal pain, nausea, fever or vomiting, consult a health care practitioner. Laxative effect may occur in which case discontinue use. Zinc supplementation can cause a copper deficiency. If you are unsure whether you are taking enough copper, consult a healthcare practitioner prior to use.
Source
Official Health Canada record, licence 80088426
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.